Search the Newsreel

Charles River Laboratories International (NYSE:CRL) EVP Sells $1,038,657.24 in Stock

Charles River Laboratories International's EVP, Shannon Parisotto, sold 3,714 shares of company stock for approximately $1.04 million, reducing her holdings by 43.59%. This transaction was conducted under a pre-arranged Rule 10b5-1 plan. The company recently reported adjusted earnings of $3.02 per share, exceeding estimates, …

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors

Charles River Laboratories International Inc. (CRL) stock fell 1.09% to $281.27 on Thursday, despite a positive trading session for the broader market. This underperformance snapped a seven-day winning streak for the company's shares. The S&P 500 Index rose 0.65%, and the Dow Jones Industrial …

Charles River Labs (CRL) CEO exercises 6,500 options and sells shares under 10b5-1 plan

Charles River Laboratories (CRL) CEO Birgit Girshick exercised stock options for 6,500 shares on August 11, 2026, at an exercise price of $179.66 per share. Simultaneously, she sold these 6,500 common shares at $279.90 per share. These transactions were conducted under a pre-arranged Rule …

Charles River (CRL) executive Parisotto exercises options, sells 3,714 shares under 10b5-1 plan

Shannon M. Parisotto, CEVP, Discovery & Safety Assessment at Charles River Laboratories International, exercised stock options for 3,714 shares at $179.66 per share and simultaneously sold the same number of shares at $279.66 per share. These transactions, executed on August 11, 2026, were conducted …

Invesco reports 2.98M-share stake in Charles River Laboratories (CRL)

Invesco Ltd., a Bermuda-based parent holding company, has reported a significant passive ownership position in Charles River Laboratories International, Inc. (CRL) common stock. The firm beneficially owns 2,984,785 shares, representing 6.2% of the outstanding common stock, held by its investment advisory clients. Invesco maintains …

Charles River Laboratories stock hits 52-week high at $285.13 By Investing.com

Charles River Laboratories International Inc. (CRL) stock has reached a 52-week high of $285.13, reflecting an 83.28% increase over the past year and a 41.4% year-to-date return. This surge follows strong second-quarter earnings that surpassed analyst expectations and led to increased price targets from …

Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Todd Spencer Chief Executive Officer - Birgit Girshick Executive Vice President and Chief Financial Officer - Glenn Coleman Full Conference Call Transcript …

Charles River Laboratories International, Inc. $CRL Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. significantly reduced its stake in Charles River Laboratories International (NYSE: CRL) by 98.4% in the first quarter, selling over 151,000 shares. Despite this, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and a $255.65 average price target. The …

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day

Charles River Laboratories International Inc. (CRL) saw its stock advance by 1.81% to $282.00 on Tuesday, marking its sixth consecutive day of gains. This performance stood out on a generally grim trading day where the S&P 500 Index fell 0.32% and the Dow Jones …

Insider Selling: Charles River Laboratories International (NYSE:CRL) Director Sells $7,901,575.00 in Stock

Charles River Laboratories International Director James Foster sold 28,733 shares of NYSE:CRL stock for approximately $7.9 million at an average price of $275, reducing his direct ownership by 47.63%. This transaction, conducted under a pre-arranged Rule 10b5-1 trading plan, comes amidst generally positive analyst …

Charles River Laboratories (CRL) EVP LaPlume reports bona fide gift of 257 shares

Joseph W. LaPlume, EVP, Corp Strategy & Develop at Charles River Laboratories International, Inc. (CRL), reported a bona fide gift of 257 shares of common stock on August 10, 2026. This transaction was a disposition at a reported per-share price of $0.00, leaving LaPlume …

Charles River (CRL) director James C. Foster exercises options and sells 28,733 shares

Charles River Laboratories International director James C. Foster exercised stock options for 28,733 shares at $179.66 per share and immediately sold them at $275.00 per share on August 10, 2026, pursuant to a Rule 10b5-1 Trading Plan. This transaction resulted in an approximate pre-tax …

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SEC Filing (Aug 11, 2026)

This SEC filing (Form 144) for Charles River Laboratories International, Inc. (CRL) details a proposed sale of 6,500 shares of common stock, valued at $1,819,350.00, acquired through the exercise of stock options on August 11, 2026. The transaction was handled by UBS Financial Services, …

Charles River Labs SVP Michael Knell sells $1.73m in stock

Michael Knell, SVP, Finance and Chief Accounting Officer at Charles River Laboratories International (NASDAQ:CRL), sold 6,645 shares totaling approximately $1.73 million on August 6, 2026, with prices ranging from $258.53 to $265.17 per share. On the same day, he acquired 2,345 shares through stock …

Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Recommendation of "Moderate Buy" by Brokerages

Charles River Laboratories International (NYSE:CRL) has received an average "Moderate Buy" rating from sixteen brokerages, with an average 12-month price target of $255.65. This follows the company exceeding quarterly earnings expectations with an adjusted EPS of $3.02 and revenue of $1.0 billion. Despite recent …

Victoria Creamer Sells 4,179 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Victoria Creamer, EVP of Charles River Laboratories International (NYSE:CRL), sold 4,179 shares for over $1.08 million, reducing her holdings by 12.21%. Despite the insider sale, the company recently reported strong quarterly earnings, beating estimates with $3.02 EPS and $1 billion in revenue, and analysts …

Michael Gunnar Knell Sells 6,645 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Michael Gunnar Knell, Chief Accounting Officer at Charles River Laboratories International (NYSE:CRL), recently sold 6,645 shares of the company's stock for approximately $1.73 million, reducing his stake by 35.92%. Despite this insider selling, the company reported strong quarterly earnings, beating analyst estimates, and has …

Charles River (CRL) finance chief sells 6,645 shares after exercising 2,345 options

Michael Gunnar Knell, SVP of Finance and Chief Accounting Officer at Charles River Laboratories International, Inc. (CRL), reported exercising 2,345 stock options and selling 6,645 shares of common stock on August 6, 2026. The options were exercised at strike prices between $179.66 and $208.44, …

James Foster (CRL) files Form 144 for 28,733-share option sale

James Foster, an insider at Charles River Laboratories International, Inc. (CRL), has filed a Form 144 indicating his plan to sell 28,733 shares of common stock. These shares will be acquired through the exercise of stock options for cash on August 10, 2026, with …

Charles River (CRL) EVP Victoria Creamer exercises options and sells 4,179 shares

Victoria L. Creamer, EVP & Chief People Officer of Charles River Laboratories International, Inc. (CRL), exercised stock options for 4,179 shares at $179.66 per share and immediately sold them for $259.16 per share on August 6, 2026. This transaction resulted in approximately $332K pre-tax …

Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $291.46, Implies 9% Upside

Analysts have raised the 12-month average price target for Charles River Laboratories International, Inc. (CRL) stock from $285.54 to $291.46, implying a 9% potential upside based on its August 7th closing price. The consensus rating from 19 analysts remains "Buy," with a majority recommending …

TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating

TD Cowen has increased its price target for Charles River Laboratories International (CRL) to $300 from $235, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst updates for the company, indicating positive sentiment following recent financial announcements. The article …

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : TD COWEN RAISES TARGET PRICE TO $300 FROM $235

TD Cowen has increased its target price for Charles River Laboratories International, Inc. (CRL.N) to $300 from $235. This update reflects a change in the analyst's outlook for the company's stock. The article is a brief news alert from Reuters regarding this financial analyst …

Charles River Laboratories International (CRL) Cuts Guidance, Is It Still Undervalued?

Charles River Laboratories International (CRL) recently cut its 2026 GAAP earnings guidance and reported a quarterly net loss, despite a strong rebound in share price momentum. The article explores two contrasting valuation narratives: one suggesting the stock is 14.7% undervalued based on primate supply …

Enterprise value to EBITDA forward of Charles River Laboratories International, Inc. – BX:RV6

This article provides a financial metric, the enterprise value to EBITDA forward, for Charles River Laboratories International, Inc. (BX:RV6). It appears to be a page from a financial data platform, likely TradingView, presenting basic information and navigation options rather than a detailed analytical report. …

Royal Bank of Canada Sells 23,345 Shares of Charles River Laboratories International, Inc. $CRL

Royal Bank of Canada reduced its stake in Charles River Laboratories International (NYSE:CRL) by 18.9% in the first quarter, selling 23,345 shares but still holding 100,311 shares valued at $17.3 million. Despite a year-over-year revenue decline, Charles River Laboratories exceeded Q2 earnings and revenue …

Charles River (CRL) Lifts Adjusted EPS Outlook After DSA Beat and Divestiture Hit Has The Bull Case Changed?

Charles River Laboratories International (CRL) reported mixed Q2 2026 results, cutting its GAAP EPS guidance due to divestiture losses but raising its full-year adjusted earnings outlook. This was driven by stronger-than-expected performance in its Discovery and Safety Assessment (DSA) segment, supported by portfolio changes …

Charles River Earnings: Improving Demand Environment Supports Stronger Near-Term Outlook

Charles River Benefits From an Improving Demand Environment Despite No Moat

Charles River Laboratories, a company specializing in animal research models and drug development services, is experiencing an improving demand environment, leading to a stronger near-term outlook. Despite not having an economic moat, the company's business strategy, which serves nearly all top biopharma players, is …

Charles River Laboratories International (NYSE:CRL) Upgraded by JPMorgan Chase & Co. to "Overweight" Rating

JPMorgan Chase & Co. upgraded Charles River Laboratories International (NYSE:CRL) to an "overweight" rating from "neutral" and significantly raised its price target to $310 from $180, suggesting a 19.18% upside. This upgrade follows Charles River's strong second-quarter performance, where it surpassed EPS and revenue …

Charles River Laboratories (NYSE: CRL) insider plans Rule 144 sale of RSU and option shares

An insider at Charles River Laboratories (NYSE: CRL) plans to sell 4,300 shares from Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) granted in 2022, along with 2,345 shares from a stock option exercise. The anticipated sale date is August 6, 2026, with …

Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $277.92, Implies 7% Upside

Analysts have raised the 12-month average price target for Charles River Laboratories International, Inc. (CRL) stock from $274.85 to $277.92, indicating a 7% potential upside from its August 5th closing price. The consensus rating among 19 analysts remains "Buy," with 14 recommendations for Buy, …

Charles River Labs (CRL) CEVP sells 5,046 shares under 10b5-1 plan

Shannon M. Parisotto, CEVP of Discovery & Safety Assessment at Charles River Laboratories International, Inc. (CRL), sold 5,046 shares of common stock at $263.00 per share on August 5, 2026. This transaction was conducted under a Rule 10b5-1 Trading Plan established on March 4, …